{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:20:09Z","timestamp":1791397209104,"version":"4.3.3"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sub Saharan African Network for TB\/HIV Research Excellence - SANTHE","award":["DEL 15-006"],"award-info":[{"award-number":["DEL 15-006"]}]},{"name":"National Institutes of Health (NIH) Fogarty International Centre","award":["D43TW010313,"],"award-info":[{"award-number":["D43TW010313,"]}],"id":[{"id":"https:\/\/ror.org\/02xey9a22","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dolutegravir (DTG)-based antiretroviral therapy (ART) is now the preferred first-line regimen for people living with HIV (PLWH) globally, including in Zimbabwe, which has an estimated adult HIV prevalence of 12.9%. While DTG offers a high genetic barrier to resistance and favourable tolerability, it has been linked to metabolic abnormalities \u2014 including abdominal obesity, hypertension, dyslipidaemia, and impaired glucose regulation \u2014 that cluster together and increase the risk of cardiovascular disease and type 2 diabetes. Data on this burden remain limited in Zimbabwe. We conducted an exploratory, hypothesis-generating cross-sectional study to estimate the burden of hyperglycaemia and dyslipidaemia, and to identify their correlates, among PLWH on first-line DTG-based ART.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to determine the burden and correlates of hyperglycaemia and dyslipidaemia in Zimbabwean adults living with HIV on first-line DTG-based ART.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional study was conducted from 20 January 2025\u201313 February 2025. The study participants were 171 PLWH receiving first-line DTG-based treatment at Parirenyatwa Group of Hospitals, in Harare, Zimbabwe. A structured questionnaire was administered to collect demographics, lifestyle information, clinical parameters and anthropometric indices. We calculated body mass index (BMI). Blood pressure measurements were taken with the participant in a resting position. Blood samples were collected and we measured HbA1c, glucose, total cholesterol (TC), HDL cholesterol (HDL-C), LDL cholesterol (LDL-C).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 171 participants, 67.8% were female, with a median age of 42.1 years (IQR 32.4\u201350.2). The majority had at least secondary education, and few were smokers (n\u2009=\u20099), while 23% reported alcohol use and 62.2% reported no regular exercise. Over half (57.9%) were overweight or obese, and 39.8% were hypertensive. The prevalence of dyslipidaemia and hyperglycaemia was 74.3% and 13.4%, respectively, with insulin resistance present in 56.1%. Non-ideal HDL-C was the most common lipid abnormality (50.5%), followed by raised LDL-C (33.3%), raised triglycerides (16%), and hypercholesterolaemia (10.3%). On multivariate analysis, increasing age was independently associated with hyperglycaemia (AOR 1.08, 95% CI 1.03\u20131.13, p\u2009=\u20090.002), while elevated blood pressure was independently associated with dyslipidaemia (AOR 2.64, 95% CI 1.03\u20136.78, p\u2009=\u20090.043).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dyslipidaemia and hyperglycaemia are highly prevalent among Zimbabwean adults on DTG-based ART, with elevated blood pressure and increasing age as key independent correlates. As this population ages on long-term ART, routine, integrated screening of BMI, blood pressure, glucose, and lipid profile is essential to mitigate cardiometabolic risk and sustain the success of DTG-based ART in Zimbabwe.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0359196","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:33:07Z","timestamp":1791394387000},"page":"e0359196","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Burden and determinants of hyperglycaemia and dyslipidaemia in Zimbabwean adults living with HIV on dolutegravir-based first-line antiretroviral therapy: A cross-sectional study"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9312-5700","authenticated-orcid":true,"given":"Ratidzo","family":"Chirimo","sequence":"first","affiliation":[{"name":"University of Zimbabwe","place":["Harare, Zimbabwe"],"department":["Faculty of Medicine and Health Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danai Tavonga","family":"Zhou","sequence":"additional","affiliation":[{"name":"University of Zimbabwe","place":["Harare, Zimbabwe"],"department":["Faculty of Medicine and Health Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9817-7108","authenticated-orcid":true,"given":"Tinashe","family":"Mudzviti","sequence":"additional","affiliation":[{"name":"University of Zimbabwe","place":["Harare, Zimbabwe"],"department":["Faculty of Medicine and Health Sciences"]},{"name":"University of the Western Cape","place":["Cape Town, South Africa"],"department":["School of Pharmacy"]},{"name":"Newlands Clinic","place":["Harare, Zimbabwe"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian Machingura","family":"Ruredzo","sequence":"additional","affiliation":[{"name":"University of Zimbabwe","place":["Harare, Zimbabwe"],"department":["Faculty of Medicine and Health Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justen","family":"Manasa","sequence":"additional","affiliation":[{"name":"University of Zimbabwe","place":["Harare, Zimbabwe"],"department":["Faculty of Medicine and Health Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Chiedza","family":"Maponga","sequence":"additional","affiliation":[{"name":"University of Zimbabwe","place":["Harare, Zimbabwe"],"department":["Faculty of Medicine and Health Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvenyika Alfred","family":"Reginald Gomo","sequence":"additional","affiliation":[{"name":"University of Zimbabwe","place":["Harare, Zimbabwe"],"department":["Faculty of Medicine and Health Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Exnevia","family":"Gomo","sequence":"additional","affiliation":[{"name":"University of Zimbabwe","place":["Harare, Zimbabwe"],"department":["Faculty of Medicine and Health Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene D.","family":"Morse","sequence":"additional","affiliation":[{"name":"Centre for Integrated Global Biomedical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York","place":["Buffalo, New York, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"pone.0359196.ref001","unstructured":"HIV\/AIDS | WHO | Regional Office for Africa. Available from: https:\/\/www.afro.who.int\/health-topics\/hivaids"},{"key":"pone.0359196.ref002","unstructured":"Zimbabwe Final Report 2020 - PHIA Project %. PHIA Project. Available from: https:\/\/phia.icap.columbia.edu\/zimbabwe2020-final-report\/"},{"key":"pone.0359196.ref003","unstructured":"Guidelines-for-HIV-Prevention-Testing-and-Treatment-of-HIV-in-Zimbabwe-August-2022. Available from: https:\/\/www.prepwatch.org\/wp-content\/uploads\/2023\/08\/Guidelines-for-HIV-Prevention-Testing-and-Treatment-of-HIV-in-Zimbabwe-August-2022"},{"issue":"2","key":"pone.0359196.ref004","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1310\/hpj4902-184","article-title":"Dolutegravir","volume":"49","author":"DJ Cada","year":"2014","journal-title":"Hosp Pharm"},{"key":"pone.0359196.ref005","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.2147\/DDDT.S84850","article-title":"Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV","volume":"9","author":"CE Kandel","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"pone.0359196.ref006","doi-asserted-by":"crossref","first-page":"20503121241260613","DOI":"10.1177\/20503121241260613","article-title":"A review of dolutegravir-associated weight gain and secondary metabolic comorbidities","volume":"12","author":"M Jemal","year":"2024","journal-title":"SAGE Open Med"},{"key":"pone.0359196.ref007","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1242\/dmm.001180","article-title":"A comprehensive definition for metabolic syndrome","volume":"2","author":"PL Huang","year":"2009","journal-title":"Dis Model Mech"},{"issue":"2","key":"pone.0359196.ref008","doi-asserted-by":"crossref","first-page":"2295435","DOI":"10.1080\/07853890.2023.2295435","article-title":"Blood glucose level and serum lipid profiles among people living with HIV on dolutegravir-based versus efavirenz-based cART; A comparative cross-sectional study","volume":"55","author":"M Jemal","year":"2023","journal-title":"Ann Med"},{"key":"pone.0359196.ref009","doi-asserted-by":"crossref","article-title":"Cardiometabolic parameters 3 years after switch to dolutegravir\/lamivudine vs maintenance of tenofovir alafenamide-based regimens","author":"RL Batterham","DOI":"10.1093\/ofid\/ofad359"},{"issue":"3","key":"pone.0359196.ref010","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.70054","article-title":"Hyperglycaemia and its risk factors among adults living with HIV on follow-up at the Hawassa City Administration, Southern Ethiopia: A cross-sectional study","volume":"8","author":"AT Hirigo","year":"2025","journal-title":"Endocrinol Diabetes Metab"},{"key":"pone.0359196.ref011","doi-asserted-by":"crossref","first-page":"23259582251395549","DOI":"10.1177\/23259582251395549","article-title":"Dyslipidemia and associated factors among people living with HIV on dolutegravir-based antiretroviral therapy in Central Uganda","volume":"24","author":"F Timbigamba","year":"2025","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"pone.0359196.ref012","doi-asserted-by":"crossref","first-page":"23259582251375873","DOI":"10.1177\/23259582251375873","article-title":"Determinants of hyperglycemia in adult people living with HIV taking dolutegravir-based antiretroviral therapy at University of Gondar Hospital, North West Ethiopia, 2022: A case-control study","volume":"24","author":"A Liknaw","year":"2025","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"pone.0359196.ref013","article-title":"1586. Impact of dolutegravir-based regimen on metabolic syndrome and its components in adults with HIV in care at Hospital Roosevelt in Guatemala City","volume":"10","author":"AJM Farf\u00e1n","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"pone.0359196.ref014","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa195","article-title":"Factors associated with weight gain in people treated with dolutegravir","volume":"7","author":"L Taramasso","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"pone.0359196.ref015","author":"AT Brennan"},{"key":"pone.0359196.ref016","article-title":"Dolutegravir-induced hyperglycaemia in a patient living with HIV","author":"M McLaughlin","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"pone.0359196.ref017","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1161\/01.ATV.17.6.1114","article-title":"Relation of high TG\u2013low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease","volume":"17","author":"J Jeppesen","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"pone.0359196.ref018","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/HIV.S529826","article-title":"Spectrum and correlates of dyslipidemia in people living with HIV on dolutegravir-based regimen attending Kabutare Hospital, Southern Rwanda: A cross-sectional study","volume":"17","author":"H Nsengumuremyi","year":"2025","journal-title":"HIV\/AIDS Res Palliat Care"},{"key":"pone.0359196.ref019","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.athplu.2025.08.001","article-title":"The association between dolutegravir based first-line antiretroviral regimens and dyslipidemia among adults living with HIV on follow-up at health facilities in Hawassa City Administration, Sidama Region: A cross-sectional study","volume":"61","author":"AT Hirigo","year":"2025","journal-title":"Atheroscler Plus"},{"key":"pone.0359196.ref020","doi-asserted-by":"crossref","first-page":"23259582251395549","DOI":"10.1177\/23259582251395549","article-title":"Dyslipidemia and associated factors among people living with HIV on dolutegravir-based antiretroviral therapy in Central Uganda","volume":"24","author":"F Timbigamba","year":"2025","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"pone.0359196.ref021","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2147\/IDR.S203813","article-title":"Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir\/abacavir\/lamivudine: Data from the SCOLTA project","volume":"12","author":"P Bagella","year":"2019","journal-title":"Infect Drug Resist"},{"issue":"3","key":"pone.0359196.ref022","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40261-014-0266-2","article-title":"Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks","volume":"35","author":"R Quercia","year":"2015","journal-title":"Clin Drug Investig"},{"issue":"11","key":"pone.0359196.ref023","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.71480","article-title":"Prevalence and correlates of hyperglycemia among people living with HIV and TB on dolutegravir-based antiretroviral therapy in Zimbabwe: A cross-sectional study","volume":"8","author":"T Zireva","year":"2025","journal-title":"Health Sci Rep"},{"key":"pone.0359196.ref024","doi-asserted-by":"crossref","first-page":"4620951","DOI":"10.1155\/2024\/4620951","article-title":"Weight and lipid levels in people living with HIV and initiating a dolutegravir-based regimen in a resource limited setting: A prospective study","volume":"2024","author":"R Chakanetsa","year":"2024","journal-title":"AIDS Res Treat"},{"key":"pone.0359196.ref025","unstructured":"HOMA Calculator [Internet]. Available from: https:\/\/www.rdm.ox.ac.uk\/about\/our-facilities-and-units\/DTU\/software\/homa"},{"key":"pone.0359196.ref026","article-title":"Changes in weight, body composition and metabolic parameters in HIV infected patients after switch from 2- to 3-drug treatment.","author":"KBH Pedersen","year":"2020"},{"issue":"7","key":"pone.0359196.ref027","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/cid\/ciz407","article-title":"Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy","volume":"70","author":"K Bourgi","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"14","key":"pone.0359196.ref028","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1177\/09564624221129410","article-title":"The risk of hyperglycemia associated with use of dolutegravir among adults living with HIV in Kampala, Uganda: A case-control study","volume":"33","author":"D Namara","year":"2022","journal-title":"Int J STD AIDS"},{"key":"pone.0359196.ref029"},{"key":"pone.0359196.ref030"},{"key":"pone.0359196.ref031","first-page":"20499361241272630","article-title":"Prevalence and factors associated with hyperglycemia among persons living with HIV\/AIDS on dolutegravir-based antiretroviral therapy in Uganda","volume":"11","author":"LH Byereta","year":"2024","journal-title":"Ther Adv Infect Dis"},{"issue":"3","key":"pone.0359196.ref032","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.70054","article-title":"Hyperglycaemia and its risk factors among adults living with HIV on follow-up at the Hawassa City Administration, Southern Ethiopia: A cross-sectional study","volume":"8","author":"AT Hirigo","year":"2025","journal-title":"Endocrinol Diabetes Metab"},{"issue":"3","key":"pone.0359196.ref033","doi-asserted-by":"crossref","first-page":"304","DOI":"10.2174\/1871526518666180723152715","article-title":"Prevalence and associated risk factors of hyperglycemia and diabetes mellitus among HIV positive patients in Tehran, Iran","volume":"19","author":"M Rasoolinejad","year":"2019","journal-title":"Infect Disord Drug Targets"},{"issue":"7","key":"pone.0359196.ref034","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(20)30042-4","article-title":"Dolutegravir-associated hyperglycaemia in patients with HIV","volume":"7","author":"M Lamorde","year":"2020","journal-title":"Lancet HIV"},{"key":"pone.0359196.ref035","first-page":"503","article-title":"Hyperglycemia after dolutegravir-based antiretroviral therapy","volume":"14","author":"W Hailu","year":"2021","journal-title":"Int Med Case Rep J"},{"issue":"9","key":"pone.0359196.ref036","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJMoa1904340","article-title":"Dolutegravir-based or low-dose efavirenz\u2013based regimen for the treatment of HIV-1","volume":"381","author":"C Kouanfack","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0359196.ref037","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1093\/jac\/dkaa330","article-title":"Incidence of diabetes in HIV-infected patients treated with first-line integrase strand transfer inhibitors: A French multicentre retrospective study","volume":"75","author":"A Ursenbach","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"pone.0359196.ref038","article-title":"Effect of dolutegravir on plasma glucose among human immunodeficiency virus patients in a community health center setting","author":"F Bahamdain"},{"key":"pone.0359196.ref039","doi-asserted-by":"crossref","first-page":"23259582251375873","DOI":"10.1177\/23259582251375873","article-title":"Determinants of hyperglycemia in adult people living with HIV taking dolutegravir-based antiretroviral therapy at University of Gondar Hospital, North West Ethiopia, 2022: A case-control study","volume":"24","author":"A Liknaw","year":"2025","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"pone.0359196.ref040","first-page":"20499361251332031","article-title":"Hyperglycemia and its associated factors among people living with HIV on dolutegravir-based antiretroviral therapy in Ethiopia: A cross-sectional study","volume":"12","author":"EF Mengistu","year":"2025","journal-title":"Ther Adv Infect Dis"},{"key":"pone.0359196.ref041","doi-asserted-by":"crossref","first-page":"23259582261426447","DOI":"10.1177\/23259582261426447","article-title":"Prevalence and factors associated with hyperglycemia among patients on dolutegravir-based antiretroviral therapy: A cross-sectional study from central Uganda","volume":"25","author":"CN Bagenda","year":"2026","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"4","key":"pone.0359196.ref042","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2337\/dci17-0005","article-title":"Diabetes and aging: Unique considerations and goals of care","volume":"40","author":"RR Kalyani","year":"2017","journal-title":"Diabetes Care"},{"key":"pone.0359196.ref043","article-title":"Aging and insulin secretion","author":"AM Chang","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"pone.0359196.ref044","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/ALN.0b013e3181799d45","article-title":"Obesity-induced insulin resistance and hyperglycemia: Etiological factors and molecular mechanisms","volume":"109","author":"JA Jeevendra","year":"2008","journal-title":"Anesthesiology"},{"issue":"6","key":"pone.0359196.ref045","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11904-017-0368-6","article-title":"The fat of the matter: Obesity and visceral adiposity in treated HIV infection","volume":"14","author":"JE Lake","year":"2017","journal-title":"Curr HIV\/AIDS Rep"},{"key":"pone.0359196.ref046","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study","author":"J Yudkin","year":"2000","journal-title":"BMJ"},{"key":"pone.0359196.ref047","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/DHPS.S395037","article-title":"Prevalence and factors associated with dyslipidemia among people living with HIV\/AIDS on follow-up care at a tertiary care hospital in Ethiopia: A cross-sectional study","volume":"15","author":"A Assefa","year":"2023","journal-title":"Drug Healthc Patient Saf"},{"key":"pone.0359196.ref048","doi-asserted-by":"crossref","first-page":"20503121241260613","DOI":"10.1177\/20503121241260613","article-title":"A review of dolutegravir-associated weight gain and secondary metabolic comorbidities","volume":"12","author":"M Jemal","year":"2024","journal-title":"SAGE Open Med"},{"issue":"7","key":"pone.0359196.ref049","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0270838","article-title":"Dyslipidemia and associated risk factors among HIV\/AIDS patients on HAART in Asmara, Eritrea","volume":"17","author":"OO Achila","year":"2022","journal-title":"PLoS One"},{"issue":"2","key":"pone.0359196.ref050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0298752","article-title":"Dietary regimens appear to possess significant effects on the development of combined antiretroviral therapy (cART)-associated metabolic syndrome","volume":"19","author":"BM Chege","year":"2024","journal-title":"PLoS One"},{"issue":"1","key":"pone.0359196.ref051","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40795-017-0132-8","article-title":"Malnutrition status and associated factors among HIV-positive patients enrolled in ART clinics in Zimbabwe","volume":"3","author":"KC Takarinda","year":"2017","journal-title":"BMC Nutr"},{"key":"pone.0359196.ref052","first-page":"20499361241306942","article-title":"The association between dolutegravir-based antiretrovirals and high blood pressure among adults with HIV in southern Ethiopia: A cross-sectional study","volume":"11","author":"AT Hirigo","year":"2024","journal-title":"Ther Adv Infect Dis"},{"key":"pone.0359196.ref053","article-title":"Hypertension among cohort of persons with human immunodeficiency virus initiated on a dolutegravir-based antiretroviral regimen in Ghana","author":"M Lartey","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"pone.0359196.ref054","doi-asserted-by":"crossref","first-page":"44837","DOI":"10.1038\/s41598-025-29159-z","article-title":"Predictors of longitudinal viral load suppression among adults receiving first line antiretroviral therapy in Central Ethiopia","volume":"15","author":"C Suwanbamrung","year":"2025","journal-title":"Sci Rep"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0359196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:33:15Z","timestamp":1791394395000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0359196"}},"subtitle":[],"editor":[{"given":"Ot\u00e1vio Augusto","family":"Chaves","sequence":"first","affiliation":[{"name":"S\u00e3o Paulo State University Institute of Biosciences Languages and Exact Sciences: Universidade Estadual Paulista Julio de Mesquita Filho Instituto de Biociencias Letras e Ciencias Exatas","place":["BRAZIL"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":54,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0359196","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]}}}